Engineering novel binding proteins from nonimmunoglobulin domains

생화학특론

발표일자 : 2010.3.17발표자 : 한원석지도교수 ( 고대 ) : Prof. 최의주지도교수 (KIST) : Prof. 윤창노

Engineering novel binding proteins from nonimmunoglobulin do-mains

Engineering novel binding proteins from nonimmunoglobulin do-mains

Therapeutic Antibodies on Market (2006)

Engineering novel binding proteins from nonimmunoglobulin do-mains

Scaffolds used for generating protein binders with prescribed specificity

Engineering novel binding proteins from nonimmunoglobulin do-mains

Scaffolds used for generating protein binders with prescribed specificity

Engineering novel binding proteins from nonimmunoglobulin do-mains

Lipocalins in drug discovery: From natural ligand-binding proteins to ‘anti-calins’

Engineering novel binding proteins from nonimmunoglobulin do-mains

Lipocalins in drug discovery: From natural ligand-binding proteins to ‘anti-calins’

Engineering novel binding proteins from nonimmunoglobulin do-mains

Affibody binding proteins developed from a small three-helix bundle scaf -fold

Engineering novel binding proteins from nonimmunoglobulin do-mains

Affibody binding proteins developed from a small three-helix bundle scaf -fold

Engineering novel binding proteins from nonimmunoglobulin do-mains

Adnectins™ are a novel class of targeted biologics derived from human fi-bronectin

Engineering novel binding proteins from nonimmunoglobulin do-mains

Comparison between camel Ig and IgG

Engineering novel binding proteins from nonimmunoglobulin do-mains

Avimers : Human A-domain in cell surface receptors

Engineering novel binding proteins from nonimmunoglobulin do-mains

Binding-site engineering strategies used with different alternative scaffolds

Engineering novel binding proteins from nonimmunoglobulin do-mains

Conclusion

IgG molecules are comparatively difficult and expensive to manufacture. Ideally, an alternative to antibodies should improve on all of limitations of IgG. Several scaffolds unrelated to IgG have now been subjected to important proof-of-princi-

ple experiments. The future application potential in research, diagnostics and therapy is readily apparent,

and some of these applications have already been demonstrated successfully. For therapeutic applications, however, the potential of alternative binding proteins has

yet to be proven, and the scaffolds may be confronted with issues such as immunogenic-ity or lack of effector functions.

Nevertheless, several alternative binding proteins are currently in preclinical studies. And the lack of effector functions may be compensated for by superior functionality or

overcome by novel effector-fusion proteins.

Engineering novel binding proteins from nonimmunoglobulin do-mains

Mergers and Acquisitions in the Biologics Sector

Engineering novel binding proteins from nonimmunoglobulin do-mains

Partnering/Licensing deals in Biologics Discovery

Engineering novel binding proteins from nonimmunoglobulin do-mains

Summary

Maybe non-IgG folds can overcome limitation of IgG Some of non-IgG folds will become Next generation antibodies Big Pharma acquired IP covering Next generation antibodies discovery and manufacture IF We Do Not Have Any IP of Next generation antibodies, The only thing We can Develop Biosimilar Careful Investigation of your Proteins will unveil novel folds that could potentially utilize as antibody-like

Thank you